Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility
New modular platform gives researchers greater control over sample and cell throughput while optimizing value SEATTLE — Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using […]
Read the full story at Financial PostOpen in the live monitor